References

ateroskleroz

Атеросклероз

Ateroscleroz

2078-256X2949-3633

НИИТПМ-филиал ИЦиГ СО РАН

ateroskleroz-600

Research Article

ОБЗОРЫ

REVIEWS

Вакцины против атеросклероза: настоящее и будущее

Atherosclerosis vaccine: the present and the future

Душкин

М. И.

Dushkin

M. I.

Михаил Иванович Душкин, д-р мед. наук, проф., зав. лабораторией

СО РАМН

Учреждение Российской академии медицинских наук Научно-исследовательский институт терапии

лаборатория молекулярно-клеточных механизмов терапевтических заболеваний

630089

ул. Б. Богаткова, 175/1

Новосибирск

SB RAMS

Institution of the Russian Academy of Medical Sciences Research Institute of Therapy

630089

B. Bogatkov str., 175/1

Novosibirsk

midushkin@soramn.ru

РАМНRAMS

2011

29032022

713544

2022

Душкин М.И.

Dushkin M.I.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://ateroskleroz.elpub.ru/jour/article/view/600

Обобщены экспериментальные данные последних лет о применении иммуномодулирующих подходов в лечении атеросклероза. Кратко рассмотрены данные о белках-мишенях антиатерогенных вакцин. Оральное или интраназальное введение белка теплового шока (HSP) и других инфекционных агентов приводит к торможению развития атеросклероза и ассоциируется с изменением баланса про- и антивоспалительных цитокинов и снижением уровня антител к HSP. Значительное снижение развития атеросклеротических бляшек вызывает иммунизация животных окисленными липопротеинами низкой плотности или пептидами модифицированного и нативного апопротеина В. Вакцина против белка, переносящего эфиры холестерина, препятствует развитию дислипопротеинемии и атеросклероза у кроликов и трансгенных мышей. Обсуждаются данные об антиатерогенном действии вакцин к цитокинам, факторам ангиогенеза и антител против CD 40 и 99. Сделано заключение, что создание комбинированной вакцины против атеросклероза является новым перспективным подходом лечения сердечно-сосудистых заболеваний.

The data of the last 15 years concerning the immunomodulatory approaches using for treatment of atherosclerosis. The data about protein-targets of anti-atherogenic vaccines are reviewed in brifly. Oral or nasal administration of heat shock protein (HSP) and other infection agents result in inhibiting of atherosclerosis development and associated with increased anti-inflammatory cytokins and decreased levels of HSP antibodies. Immunization of animals using oxidized lipoprotein low density or modified apolipoprotein B peptide was found to result in significant reduction of plaque evelopment. Vaccine against a peptide of cholesteryl ester transfer protein is protected the dislipiproteinemia development and reduced atherosclerosis in rabbits. The data about anti-atherosclerotic effects of vaccines to cytokins and angiogenesis factors and antibodies against CD40 is reviewed in brief. We conclude that combined vaccine creation is new perspective approach of cardiovascular disease treatment.

атеросклерозвакциныиммунитетвоспалениелипопротеидный обмен

atherosclerosisvaccineimmunityinflammationlipoprotein metabolism

References1

Maron R., Sukhova G., Faria A. M. et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice // Circulation. 2002. Vol. 106. P. 1599–1601.

Frostegard J. Autoimmunity, oxidized LDL and cardiovascular disease // Autoimmun Rev. 2002. Vol. 1. P. 233–237.

Walton K. A., Cole A. L., Yeh M. et al. Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2 // Arterioscler. Tromb. Vasc. Biol. 2003. Vol. 23. P. 1197–1203.

Murray C. J., Lopes A. D. Alternative projections of mortality and disability by cause 1990-2020 global bur den of disease study // Lancet. 1997. Vol. 346. P. 1498–1504.

Skalen K., Gustafsson M., Rydberg E. K. et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis // Nature. 2002. Vol. 417. P. 750–754.

Sloan-Lancaster J., Allen P. M. Altered peptide ligandinduced partial T cell activation: molecular mechanisms and role in T cell biology // Annu Rev. Immunol. 1996. Vol. 14. P. 1–27.

Wick G., Xu Q. Atherosclerosis – an autoimmune disease // Exp. Gerantol. 1999. Vol. 34. P. 559–566.

Williams K. J., Tabas I. The response-to-retention hypothesis of atherogenesis reinforced // Curr. Opin. Lipidol. 1998. Vol. 9. P. 471–474.

Hu X., Dietz J. D., Xia C. et al. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition // Endocrinology. 2009. Vol. 150. P. 2211–2219.

Edfeldt K., Swedenborg J., Hannsson G. K., Yan Z. Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation // Circulation. 2002. Vol. 105. P. 1158–1161.

van Es T., van Puijvelde G. H., Michon I. N. et al. IL-15 aggravates atherosclerotic lesion development in LDL receptor deficient mice // Vaccine. 2011. Vol. 29. P. 976–983.

Xu X. H., Shah P. K., Faure E. et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDl // Circulation. 2001. Vol. 104. P. 3103–3108.

Taylor-Robinson D., Thomas B. J. Chlamidia pneumoniae in arteries: the fact, there interpretation, and future studies // J. Clin. Pathol. 1998. Vol. 51. P. 793–797.

Perschinka H., Mayr M., Milloning G. et al. Crossreactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis // Arterioscler. Tromb. Vasc. Biol. 2003. Vol. 23. P. 1060–1065.

Afek A., George J., Gilburg B. et al. Immunization of LDL receptor deficient mice with heat shok protein 65promotes early atherosclerosis // J. Autoimmun. 2000. Vol. 14. P. 115–121.

Xu Q., Dietrich H., Steiner H. J. et al. Induc tion of atherosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65 // Arte rioscler. Tromb. Vasc. Biol. 1992. Vol. 12. P. 789–799.

Lamb D. J., Ferns G. A. The magnitude of the immune to heat shock protein-65 following BCG immunization is associated with the extent of experimental athe rosclerosis // Atherosclerosis. 2002. Vol. 165. P. 231–240.

Shibata Y., Ohata H., Yamashita M. et al. Immunologic response enhances atherosclerosis-type 1 helper T cell (Th1) totype 2 helper T cee (Th2) shift and clacificated atherosclerosis in BCG-treated apolipoprotein E-knockaut mice// Trans. Res. 2007. Vol. 149. P. 62–69.

Frostegard J., Ulfgren A. K., Niberg P. et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophagestimulating cytokines // Atherosclerosis. Vol. 145. P. 33–43.

Zhou X., Caligiuri G., Hamsten A. et al. LDL immunization induces T-cell-dependent antibody formation and protection against athero sclerosis // Arterioscler. Tromb. Vasc. Biol. 2001. Vol. 21. P. 108–114.

Zhou X., Nicoletti A., Elhage R., Hansson G. K. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein knockout mice // Circulation. 2000. Vol. 102. P. 2919–2922.

Mallat Z., Gojova A., Brun V. et al. Induction of regulatory T cell tipe 1 response reduces the development of atherosclerosis in apolipoprotein E-knockaut mice // Circulation. 2003. Vol. 108. P. 455–458.

Robertson A. K., Rudling M., Zhou X. et al. Distruption of TGF-beta signaling in T cells accelerates atherosclerosis // J. Clin. Invest. 2003. Vol. 112. P. 1342–1350.

Tupin E., Nicoltti A., Ethage R. et al. Cd1d-dependent activation of NKT cells aggravates atherosclerosis // J. Exp. Med. 2004. Vol. 199. P. 417–422.

Caligiuri G., Nicoletti A., Poirier B., Hansson G. K. Protective immunity against atherosclerosis carried by B cells of hypercholesterolic mice // J. Clin. Invest. 2002. Vol. 109. P. 745–753.

Makheja A. N., Bloom S., Muesing R. et al. Anti-inflammatory drugs in experimental atherosclerosis. 7. Spontaneous atherosclerosis in WHHL rabbits and inhibition by cortisone acetate // Atherosclerosis. 1989. Vol. 76. P. 115–161.

Andersen H. O., Holm P., Stenger S. et al. Dose-dependent suppression of transplantant atherosclerosis in aorta-allografted, cholesterol-clamped rabbits. Suppression not eliminated by the cholesterol-raising effect of cyclosporine // Arterioscler. Tromb. Vasc. Biol. 1997. Vol. 17. P. 2515–2523.

Gordon S. Pattern recognition receptors: doubling up for the innate immune respose // Cell. 2002. Vol. 111. P. 927–930.

Душкин М. И. Влияние оксистеролов и аторвастатина на ЛПС-индуцированную секрецию фактора некроза опухоли и интерлейкина-10 макрофагами мыши / М. И. Душкин [и др.] // Бюл. экперим. биол. мед. – 2006. – Т. 141, № 2. – С. 194–197.

Перминова О. М. Влияние цитокинов на метаболизм холестерина в макрофагах / О. М. Перминова, Н. Н. Вольский, М. И. Душкин. – Система цитокинов: теоретические и клинические аспекты / под ред. В. А. Козлова, С. В. Сенникова. – Новосибирск, 2004. – С. 109–121.

Душкин М. И. Интеграция сигнальных путей регуляции липидного обмена и воспалительного ответа / М. И. Душкин, Е. Н. Кудимова, Я. Ш. Шварц // Цитокины и воспаление. – 2007. – № 2. – С. 12–18.

Rittershaus C. W., Miller D. P., Thomas L. J. et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis // Arterioscler. Tromb. Vasc. Biol. 2000. Vol. 20. P. 2106–2112.

Ansell B., Hobbs F. D. The potential for CETP inhibition to reduce cardiovascular disease risk // Curr. Med. Res. Opin. 2006. Vol. 22. P. 2467–2478.

Gaofu Q., Dan M., Jie W. et al. Long-lasting specific antibodies against CETP induced by subcutaneous and mucosal administration of a 26-amino acid CETP epitope carried by shok protein 65 kDa in absence of adjuvants // Vac cine. 2004. Vol. 22. P. 3187–3194.

Gaofu Q., Jun L., Xin Y. et al. Vaccinating rabbits with a cholesteryl es ter protein (CETP) b-cell epitope carried by HSP-65 for inducting anti-CETP antibodies and reducing aortic lesions in vivo // J. Cardiovasc. Pharmacol. 2005. Vol. 45. P. 591–598.

Mao D., Kai G., Gaofu Q. et al. Intramuscular immunization with DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis // Vaccine. 2006. Vol. 24. P. 4942–4950.

Qi G., Li J., Wang S. et al. A chimeric peptide of intestinal trefoil factor containing cholesteryl ester transfer protein B cell epitope significantly inhibits atherosclerosis in rabbits after oral administration // Peptides. 2010 (in press).

Chyu K. Y., Nilsson J., Shah P. K. Active and passive immunization for atherosclerosis // Curr. Opin. Mol. Ther. 2007. Vol. 9. P. 176–182.

Palinski W., Miller E., Witztum J. L. Immunization of LDL receptor-deficient rabbits with homologous malon-dialdehyde-modified LDL reduces atherogenesis // Proc. Natl. Acad. Sci. USA. 1995. Vol. 92. P. 821–825.

Ameli S., Hultgardh-Nilsson A., Regnstrom J. et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hyper cho leste rolemic rab bits // Arterioscler. Thromb. Vasc. Biol. 1996. Vol. 16. P. 1074–1079.

Freigang S., Horkko S., Miller E. et al. Immunization of LDL receptor-dificient mice with homologous malondialdehyde-modified and na tive LDL reduces progres sion of atherosclerosis by me chanism sotherthan induction of high titers of anti bodies to oxidative epi topes // Arterioscler. Tromb. Vasc. Biol. 1998. Vol. 18. P. 1972–1982.

Gorge J., Afeck A., Gilburd B. et al. Hyperimmunization of apo-E-deficient mice with homologous MDA LDL suppresses early atherogenesis // Atherosclerosis. 1998. Vol. 138. P. 147–152.

Palinski W., Rosenfeld M. E., Yla-Herttuala S. et al. Low density lipo protein undergoes modification in vivo // Proc. Natl. Acad. Sci. USA. 1989. Vol. 86. P. 1372–1376.

Salonen J. T., Yla-Hertuala S., Yamamoto R. et al. Autoantibody against oxidized LDL and progression of ca rotid atherosclerosis // Lancet. 1992. Vol. 339. P. 883–887.

Pedersen T. X., Binder C. J., Fredrikson G. N. et al. The pro-inflammatory effect of uraemia overrules the antiatherogenic potential of im mu nization with oxidized LDL in apoE-/- mice // Nephrol. Dial. Transplant. 2010. Vol. 8. P. 2486–2491.

Fredrison G. N., Hedblad B., Berglund G. et al. Identification of immune responses against aldechyde-modified peptide sequences in apoB associated with cardiovascular disease // Arterioscler. Thromb. Vasc. Biol. 2003. Vol. 23. P. 872–878.

Fredrikson G. N., Soderberg I., Lindholm M. et al. Inhibition of athe rosclerosis in apoE-null mice by immunization with apoB-100 peptide sequences // Ibid. P. 879–884.

Schipu A., Bengtsson J., Soderberg I. et al. Recombinant human antibodies against aldechyde-modified apoB-100 peptide sequences inhibit atherosclerosis // Circulation. 2004. Vol. 110. P. 2047–2052.

Fredrikson G. N., Björkbacka H., Söderberg I. et al. Treatment with apo B peptide vac cines inhibits atherosclerosis in human apo B-100 transgenic mice without inducing an increase in pep tide-specific antibodies // J. Intern. Med. 2008. Vol. 264. P. 563–570.

Wigren M., Kolbus D., Dunér P. et al. Evidence for a role of regulatory T cells in mediating the athe roprotective effect of apolipoprotein B peptide vaccine // J. Intern. Med. 2010. Vol. 266. P. 1365–1373.

Binder C. J., Horkko S., Dewan A. et al. Pneumococcal vaccination decreases atherosclerotic lesion formation:molecular mimicry between Streptococcus pneumoniae and oxidized LDL // Nat. Med. 2003. Vol. 9. P. 736–743.

Nguyen J. T., Myers N., Palaia J. et al. Humoral responses to oxidized low-density lipoprotein and related bacterial anti gens after pneumococcal vaccine // Transl. Res. 2007. Vol. 150. P. 172–179.

Hauer A. D, Uyttenhove C., de Vos P. et al. Blokade of interleukin-12 function by protein vaccination attenuates atherosclerosis // Circulation. 2005. Vol. 112. P. 1054–1062.

Hauer A.D., van Puijvelde G.H., Peterse N. Vaccination against VEGFR 2 atte nuates initiation and progression of atherosclerosis // Arterioscler. Thromb. Vasc. Biol. 2007. Vol. 27. P. 2050–2057.

Petrovan R. J., Kaplan C. D., Reisfeld R. A., Curtiss L. K. DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice // Arterioscler. Thromb. Vasc. Biol. 2007. Vol. 27. P. 993–995.

van Wanrooij E. J., de Vos P., Bixel M. G. et al. Vaccination against CD99 inhibits atherogenesis in low-density lipoprotein receptor-deficient mice // Car diovasc. Res. 2008. Vol. 78. P. 590–596.

Hauer A. D., Habets K. L., van Wanrooij E. J. et al. Vaccination against TIE2 reduces atherosclerosis // Atherosclerosis. 2009. Vol. 204. P. 365–371.

Chen Y., Inobe J., Kuchroo V. K. et al. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells // Proc. Natl. Acad. Sci. USA. 1996. Vol. 93. P. 388–391.

Faunce D. E., Terajewicz A., Stein-Streilein J. Cutting edge: in vitro-generated tolerogenic APC induce CD8+ T regulatory cells that can suppress oncoing experimental autoimmune encephalomyelitis // J. Immunol. 2004. Vol. 172. P. 1991–1995.

Harats D., Yacov N., Gilburg B. et al. Oral tolerance with heat shock protein 65 attenuates My cobacterium tuberculosis-induced and high-fad-diet-driven atherosclerosis lesions // J. Am. Coll. Cardiol. 2002. Vol. 40. P. 1333–1338.

Pockley A. G., Georgiades A., Thulin T. et al. Serum heat shock protein 70 levels pre dict the development of atherosclerosis in subjects with established hypertension // Hypertension. 2003. Vol. 42. P. 235–238.

van Puijvelde G. H. M., Hauer A. D., de Vos P. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis // Circulation. 2006. Vol. 114. P. 1968–1976.

Wigren M., Bengtsson D., Duner P. Atheroprotective effects of alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells // Circulation Research. 2009. Vol. 104. P. e62–e70.

Lamb D. J., Ferns G. A. The magnitude of the immune response to heat shock protein-65 following BCG immunization is associated with the extent of experimental atherosclerosis // Atherosclerosis. 2002. Vol. 165. P. 231–240.

Jan M., Meng S., Chen N. C., Mai J., Wang H., Yang X. F. Inflammatory and autoimmune reactions in athe rosclerosis and vaccine design informatics // J. Biomed. Biotechnol. 2010. 459798. 16 p. Review

The authors declare that there are no conflicts of interest present.